Quality of life and CAR-T cell therapy in children, adolescents, and young adults with haematological malignancies

Lancet Oncol. 2019 Dec;20(12):1625-1626. doi: 10.1016/S1470-2045(19)30641-2. Epub 2019 Oct 9.

Authors

Fabio Efficace¹, Marco Vignetti²

Affiliations

¹ Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, 00161 Rome, Italy. Electronic address: f.efficace@gimema.it.
² Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, 00161 Rome, Italy.

PMID: 31606418
DOI: 10.1016/S1470-2045(19)30641-2

No abstract available

Publication types

Comment

MeSH terms

Adolescent
B-Lymphocytes
Cell- and Tissue-Based Therapy
Child
Hematologic Neoplasms*
Humans
Immunotherapy, Adoptive
Patient Reported Outcome Measures
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Quality of Life
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
Young Adult

Substances

Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
tisagenlecleucel